Nurix therapeutics expands its board of directors with the addition of two industry leaders

San francisco, sept. 30, 2021 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of judith a. reinsdorf and paul m. silva to its board of directors, effective october 1, 2021. ms. reinsdorf is the former executive vice president and general counsel of johnson controls international, and mr. silva is the former senior vice president, chief accounting officer at vertex pharmaceuticals incorporated.
NRIX Ratings Summary
NRIX Quant Ranking